Printer friendly

Lage toxiciteit / immunogeniciteit

Muyldermans S. Single domain camel antibodies: current status. J Biotechnol. 2001 Jun; 74 (4): 277-302.

Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh-G, Gobert M, Muyldermans S, De Baetselier P, Revets H. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer. 2002 Mar 20; 98 (3): 456-62.

Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004 Apr 15; 64 (8): 2853-7.

Gibbs WW. Nanobodies. Sci Am. 2005 Aug; 293 (2): 78-83.

Verheesen P, de Kluijver A, van Koningsbruggen S, de Brij M, de Haard HJ, van Ommen GJ, van der Maarel SM, Verrips CT. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet. 2006 Jan 1; 15 (1): 105-11.